Zoltán Papp looks at the current management of acute heart failure and the 2016 ESC guidelines and the inotropic agents dobutamine, dopamine, levisomendan and phosphodiesterase III (PDE III) inhibitors and their use in cases with hypotension and hypofusion.
Alexandre Mebazaa covers the aetiology of acute heart failure, covering precipitating factors and the evidence behind acute management.
Dirk von Lewinski takes a look at the role of inodilators in heart failure, discussing the most appropriate clinical scenario for their use in this webinar first broadcast in August 2017.
George Giannakoulas focuses on the clinical practice of repetitive inodilator use in AdHF, talking through a case and identifying the most appropriate candidates for this treatment.
Gerhard Pölzl discusses how best to choose an endpoint when researching heart failure – delving into limitations of composite endpoints, and advantages of other metrics.
Johann Altenberger discusses clinical endpoints in heart failure; reviewing the basis for the current urging to place more emphasis on patient reported outcomes of quality of life as a measure.
Dr. John T Parissis brings the guidelines into a more practical context, covering the theory before embarking on a discussion of clinical cases.
Maati Kivikko reviews the current state of the evidence surrounding repetitive use of inodilators in advanced heart failure.
Veli-Pekka Harjola covers cardiogenic shock as the only concrete indication for inotropes, urging the need for better understanding of multiorgan dysfunction.
Johann Altenberger discusses the rationale for levosimendan in patients with advanced heart failure.
Gerhard Pölzl discusses the repetitive use of levosimendan in heart failure patients.
Gabriella Malfatto discusses her findings of using levosimendan in treating advanced heart failure detailing the haemodynamic effects due to the active metabolite calcium sensitizer OR-1896.
Zoltán Papp looks at the current management of acute heart failure and the 2016 ESC guidelines and the inotropic agents dobutamine, dopamine, levisomendan and phosphodiesterase III (PDE III) inhibitors.
Veil-Pekka Horjola looks at the clinical indications for inotropic agents detailing the main problem with these is hypoperfusion (hypotension, decreased renal function).
Kristjan Karason discusses patients from the EuroHeart Failure Survey II (EHFS II), the 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.
Detlef Kindgen-Milles discussed cardiorenal syndromes and the bi-directional interaction between heart and kidneys.
John Parissis visits the therapeutic approaches for cardiorenal syndrome and how its management is difficult – there are many options but the mortality rate remains unimproved.
Finn Gustafsson concludes that renal dysfunction and worsening renal function are common in acute decompensated heart failure and renal dysfunction is associated with increased mortality.
Matti Kivikko presents the ESC Guidelines for diagnosis and treatment of acute and chronic heart failure.
Carsten Tschöpe shares some case studies including a 74 year-old male with ischaemic cardiomyopathy, a 62 year-old obese female with angina and hypertension.